Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Non-Current Deffered Revenue (2024 - 2026)

Perspective Therapeutics' Non-Current Deffered Revenue history spans 3 years, with the latest figure at $26.6 million for Q1 2026.

  • On a quarterly basis, Non-Current Deffered Revenue changed 0.0% to $26.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $26.6 million, a 0.0% change, with the full-year FY2025 number at $26.6 million, changed 0.0% from a year prior.
  • Non-Current Deffered Revenue hit $26.6 million in Q1 2026 for Perspective Therapeutics, roughly flat from $26.6 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for CATX hit a ceiling of $26.6 million in Q1 2024 and a floor of $26.6 million in Q1 2024.
  • Historically, Non-Current Deffered Revenue has averaged $26.6 million across 3 years, with a median of $26.6 million in 2024.
  • The widest YoY moves for Non-Current Deffered Revenue: up 0.0% in 2025, down 0.0% in 2025.
  • Tracing CATX's Non-Current Deffered Revenue over 3 years: stood at $26.6 million in 2024, then changed by 0.0% to $26.6 million in 2025, then changed by 0.0% to $26.6 million in 2026.
  • Business Quant data shows Non-Current Deffered Revenue for CATX at $26.6 million in Q1 2026, $26.6 million in Q4 2025, and $26.6 million in Q3 2025.